Nowadays, studies have shown different prostate cancer treatments with anti-angiogenic drugs involving VEGF inhibition, which is the primary regulator of the proliferation and migration of endothelial cells [25]. The gene discussed is VEGFA; the disease is Familial prostate cancer.